과제정보
연구 과제 주관 기관 : National Research Foundation of Korea (NRF)
참고문헌
- Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005;23:3227-3234. https://doi.org/10.1200/JCO.2005.09.985
- Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-2459. https://doi.org/10.1200/JCO.2005.11.890
- Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388. https://doi.org/10.1056/NEJMoa0909530
- Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128. https://doi.org/10.1016/S1470-2045(09)70364-X
- Cho BC, Im CK, Park MS, et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007;25:2528-2533. https://doi.org/10.1200/JCO.2006.10.4166
- Sim SH, Han SW, Oh DY, et al. Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. Lung Cancer 2009;65:204-207. https://doi.org/10.1016/j.lungcan.2008.11.006
- Viswanathan A, Pillot G, Govindan R. Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2005;50:417-418. https://doi.org/10.1016/j.lungcan.2005.07.004
- Kaira K, Naito T, Takahashi T, et al. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer 2010;68:99-104. https://doi.org/10.1016/j.lungcan.2009.05.006
- Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007;13:3731-3737. https://doi.org/10.1158/1078-0432.CCR-07-0088
- Comis RL. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. Oncologist 2005;10:467-470. https://doi.org/10.1634/theoncologist.10-7-467
- Leveque D. Pharmacokinetics of gefitinib and erlotinib. Lancet Oncol 2011;12:1093.
- Lee DH, Kim SW, Suh C, Yoon DH, Yi EJ, Lee JS. Phase II study of erlotinib as a salvage treatment for non-smallcell lung cancer patients after failure of gefitinib treatment. Ann Oncol 2008;19:2039-2042. https://doi.org/10.1093/annonc/mdn423
- Wong AS, Soong R, Seah SB, et al. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib- sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol 2008;3:400-404. https://doi.org/10.1097/JTO.0b013e318168c801
- Costa DB, Nguyen KS, Cho BC, et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008;14:7060-7067. https://doi.org/10.1158/1078-0432.CCR-08-1455
- Grossi F, Rijavec E, Dal Bello MG, et al. The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. Cancer Chemother Pharmacol 2012;69:1407-1412. https://doi.org/10.1007/s00280-012-1848-4
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247. https://doi.org/10.1016/j.ejca.2008.10.026
- Kim YT, Kim TY, Lee DS, et al. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer 2008;59:111-118. https://doi.org/10.1016/j.lungcan.2007.08.008
- Tomizawa Y, Fujita Y, Tamura A, et al. Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer 2010;68:269-272. https://doi.org/10.1016/j.lungcan.2009.06.025
- Choong NW, Dietrich S, Seiwert TY, et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges: role of EGFR mutation. Nat Clin Pract Oncol 2006;3:50-57. https://doi.org/10.1038/ncponc0400
- Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012;44:852-860. https://doi.org/10.1038/ng.2330
- Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792. https://doi.org/10.1056/NEJMoa044238
- Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73. https://doi.org/10.1371/journal.pmed.0020073
- Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043. https://doi.org/10.1126/science.1141478
- Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68:9479-9487. https://doi.org/10.1158/0008-5472.CAN-08-1643
- Jang SH. Long term therapeutic plan for patients with non-small cell lung cancer harboring EGFR mutation. Tuberc Respir Dis (Seoul) 2014;76:8-14. https://doi.org/10.4046/trd.2014.76.1.8
- Becker A, Crombag L, Heideman DA, et al. Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer 2011;47:2603-2606. https://doi.org/10.1016/j.ejca.2011.06.046
- Guo R, Chen X, Wang T, Zhang Z, Sun J, Shu Y. Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer 2011;11:90. https://doi.org/10.1186/1471-2407-11-90
- Li XD, Geng YT, Wu CP, et al. Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer. Onkologie 2010;33:466-469. https://doi.org/10.1159/000319109
- Yoshimoto A, Inuzuka K, Kita T, Kawashima A, Kasahara K. Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. Am J Med Sci 2007;333:221-225. https://doi.org/10.1097/MAJ.0b013e31803b8acb
- Hata A, Katakami N, Yoshioka H, et al. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection. Lung Cancer 2011;74:268-273. https://doi.org/10.1016/j.lungcan.2011.03.010
- Koyama N, Uchida Y. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations. Anticancer Res 2013;33:5083-5089.
- Vasile E, Tibaldi C, Chella A, Falcone A. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib. J Thorac Oncol 2008;3:912-914. https://doi.org/10.1097/JTO.0b013e318180275e
- Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181. https://doi.org/10.1038/nrc2088
피인용 문헌
- Gefitinib : Liver toxicity: case report vol.1629, pp.1, 2015, https://doi.org/10.1007/s40278-016-23395-x
- Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation vol.83, pp.5, 2015, https://doi.org/10.1007/s00280-019-03790-w
- Treatment of Hominis placenta pharmacopuncture for a patient with mild neurocognitive disorder: Case report vol.22, pp.4, 2015, https://doi.org/10.3831/kpi.2019.22.037
- Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis : A successful case report and review vol.100, pp.25, 2021, https://doi.org/10.1097/md.0000000000026450